Rabbit anti-PAX8, clone ZR1 (Monoclonal)

PAX-8 is expressed in the thyroid (and associated carcinomas), non-ciliated mucosal cells of the fallopian tubes and simple ovarian inclusion cysts, but not normal ovarian surface epithelial cells. PAX-8 is expressed in a high percentage of ovarian serous, endometrioid, and clear cell carcinomas, but only rarely in primary ovarian mucinous adenocarcinomas. Studies have also found PAX-8 expressions in renal tubules as well as renal carcinoma, nephroblastoma and seminoma. Over 98% of clear cell RCCs, 90% of papillary RCCs, and 95% of oncocytomas were positive for PAX-8, frequencies which are similar or better than for PAX-2. Similarly, the absence of expression of PAX-8 in breast and other non-GYN carcinomas other than those primary to the thyroid indicates that PAX-8 is an important new marker of ovarian cancer and a useful marker for the differential diagnoses in lung and neck tumors, or tumors at distant sites where primary lung carcinoma or thyroid carcinoma are possibilities. PAX-8, combined with organ system-specific markers such as uroplakin, mammaglobin, and TTF-1 can be a very useful panel to determine the primary site of invasive micropapillary carcinomas of ovary from bladder, lung, and breast. Unlike the polyclonal anti-PAX-8 antibody, the ZR1 rabbit monoclonal antibody does not react with pancreatic neuroendocrine tumors and thymic tumors. Pretreatment: Heat induced epitope retrieval in in 50 mM Tris buffer pH9.0, for 15 minutes is required for IHC staining on formalin-fixed, paraffin embedded tissue sections. Note: Dilution of the antibody in 10% normal goat serum followed by a goat anti-rabbit secondary antibody-based detection is recommended. Control tissue Ovarian serous carcinoma; staining nuclear